Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Apogee Therapeutics, Inc.NASDAQ: APGE
Common Stock · Q2 FY2026 · quarter ended Jun 2026
Common stock broadly unchanged from a year ago
Common stock stood at $1K at the end of Q2 FY2026, up 0.0% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at -92.4% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
- Common stock increased in 1 of the last 3 fiscal years.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +0.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 1K USD
- Year-over-year change
- +0.0%
- 3-year CAGR
- -92.4%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1K | +0.0% |
| FY2024 | 2024-12-31 | 1K | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 2.25M | — |
Common Stock vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +0.0% is the 8th highest of 10, against a peer median of +19.7%.
- Common stock amounts to 0.0% of total assets for APGE, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $2.49B USD | +69.0% | +14.5% | 207.8% | |
| Mar 2026 | $419K USD | +15.7% | +15.2% | 0.1% | |
AAPGAscentage Pharma Group International | Dec 2025 | CN¥256.16K CNY | +19.7% | +12.5% | 0.0% |
| Sep 2026 | $100K USD | +170.3% | +44.7% | 0.0% | |
| Jun 2026 | $49K USD | +25.6% | +30.4% | 0.0% | |
| Sep 2026 | $9K USD | +12.5% | — | 0.0% | |
| Jun 2026 | $7K USD | +0.0% | +5.3% | 0.0% | |
IRONDisc Medicine, Inc. | Sep 2026 | $4K USD | +33.3% | +26.0% | 0.0% |
| Jun 2026 | $1K USD | +0.0% | -92.4% | 0.0% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Peer median (excluding APGE) | — | +19.7% | +15.2% | 0.0% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.